Wikipedia -WSS

Wikipedia

author：fashion 2025-09-29 21:25:38 - browse：5

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Scientists uncover potential path to treating deadly childhood tumor

explore

WSS

Life sciences deals on track to hit lowest point since 2017

People with mental disorders often marry others with same

Akero's treatment for NASH falls short in cirrhosis study

A revolution in caring for preterm infants

U.K. decision on ALS drug has neurologists, advocates up in arms

Akero's treatment for NASH falls short in cirrhosis study

Wikipedia

Wikipedia

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Republican states more likely to report Covid vaccine side effects

The high cost of giving birth even with insurance

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Medicare proposal to cover medical devices draws a mixed reaction

Young boy dies in trial for Pfizer Duchenne gene therapy

Peter Hotez and the public health issue of online harassment

What's changing in Medicare's open enrollment this year?

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

knowledge

Wellcome Trust names Røttingen as its new CEO

U.K. decision on ALS drug has neurologists, advocates up in arms

Young boy dies in trial for Pfizer Duchenne gene therapy

Massive project maps cells in human brain in unprecedented detail

UnitedHealth, in a surprise, takes aim at Steward’s physician group

European regulators consider appeal over Amylyx ALS drug

explore

focus

explore

focus